Categories covered by this talk
About this talk
Psilocybin has received a ‘breakthrough’ designation by the FDA for treatment resistant depression and psilocybin-assisted therapy is poised for approval in the near future. This talk will describe the pharmacology of psilocybin, review currently available clinical data, and discuss a framework for approaching psilocybin therapy in persons with mental illness.
Have you got yours yet?
Our All-Access Passes are a must if you want to get the most out of this event.
Check them out
Benjamin Malcolm, PharmD, MPH is a Board Certified Psychiatric Pharmacist (BCPP) with a special interest in psychedelic substances.
Proudly supported by
Your logo could go here!
If you'd like to get your brand in front of attendees contact us